NCT06692777View on ClinicalTrials.gov

Evaluation of the Hypolipidemic Effect of Bergavit by a Human Trial.

NACompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 21, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

October 31, 2024

Conditions
Hyperlipidemia
Interventions
DIETARY_SUPPLEMENT

Bergavit

Subjects treated with Bergavit capsule intake of 150 mg/die of pure flavonoids for 4 months.

DIETARY_SUPPLEMENT

Placebo

Subjects will take capsule equivalent amount of maltodextrin for 4 months.

Trial Locations (1)

Unknown

Chung Shan Medical University, Taichung

All Listed Sponsors
lead

Chung Shan Medical University

OTHER

NCT06692777 - Evaluation of the Hypolipidemic Effect of Bergavit by a Human Trial. | Biotech Hunter | Biotech Hunter